胰高血糖素样肽-1
参考

↑  .   [2024-03-10]. （原始内容存档于2024-03-10）.
↑  张勤凤, 武晓泓. 胰高血糖素样肽1受体表达及其生理功能的研究进展 [J] . 中华糖尿病杂志,2013,5 (3): 183-186. DOI: 10.3760/cma.j.issn.1674-5809.2013.03.013
↑  .   [2024-03-10]. （原始内容存档于2024-03-10）.
↑  .   [2024-03-10]. （原始内容存档于2024-03-10）.
↑  Mapelli C, Natarajan SI, Meyer JP, Bastos MM, Bernatowicz MS, Lee VG, Pluscec J, Riexinger DJ, Sieber-McMaster ES, Constantine KL, Smith-Monroy CA, Golla R, Ma Z, Longhi DA, Shi D, Xin L, Taylor JR, Koplowitz B, Chi CL, Khanna A, Robinson GW, Seethala R, Antal-Zimanyi IA, Stoffel RH, Han S, Whaley JM, Huang CS, Krupinski J, Ewing WR. Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. J Med Chem. 2009 Dec 10;52(23):7788-99. doi: 10.1021/jm900752a. PMID 19702274.
↑  . 术语在线. 全国科学技术名词审定委员会.  （简体中文）
↑  Marie K. Holt, James E. Richards, Daniel R. Cook, Daniel I. Brierley, Diana L. Williams, Frank Reimann, Fiona M. Gribble, Stefan Trapp; Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food. Diabetes 1 January 2019; 68 (1): 21–33. https://doi.org/10.2337/db18-0729
↑  邹大进. 葡萄糖依赖性促胰岛素多肽：从基础研究到临床研究[J]. 中华糖尿病杂志,2023,15(05)：474-478.DOI:10.3760/cma.j.cn115791-20230211-00050
↑  胡质毅,龙綮新,王珣章.重组GIP蛋白的原核优化表达及其生物活性的研究[J].生物化学与生物物理进展, 2006, 033(011):1086-1093.DOI:10.3321/j.issn:1000-3282.2006.11.010.
↑  Wu J, He T, Guo P, Cai F, Zhao C. An Electrochemical Sense Array Based on Aptamer and Biotin-Avidin System for the Selective Detection of Glucagon-Like Peptide-1. Clin Lab. 2019 Jun 1;65(6). doi: 10.7754/Clin.Lab.2018.181208. PMID 31232038.
↑  Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Eur J Intern Med. 2009 Jul;20 Suppl 2:S319-28. doi: 10.1016/j.ejim.2009.05.010. Epub 2009 Jun 21. PMID 19580951.
↑  Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab. 2003 Apr;88(4):1772-9. doi: 10.1210/jc.2002-021479. PMID 12679472.
↑  Ehsasatvatan, M., Baghban Kohnehrouz, B. Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes. Sci Rep 13, 17778 (2023). https://doi.org/10.1038/s41598-023-45185-1
↑  Murage EN, Gao G, Bisello A, Ahn JM. Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. J Med Chem. 2010 Sep 9;53(17):6412-20. doi: 10.1021/jm100602m. PMID 20687610.
↑  GRADE Study Research Group; Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, Butera NM, Cohen RM, Crandall JP, Kahn SE, Krause-Steinrauf H, Larkin ME, Rasouli N, Tiktin M, Wexler DJ, Younes N. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med. 2022 Sep 22;387(12):1063-1074. doi: 10.1056/NEJMoa2200433. PMID 36129996; PMCID: PMC9829320.
↑  Modlin I M, Kidd M. Ernest Starling and the discovery of secretin[J]. Journal of Clinical Gastroenterology, 2001, 32(3): 187-192.
↑  Luhovyy B L, Kathirvel P. Food proteins in the regulation of blood glucose control[M]//Advances in Food and Nutrition Research. Academic Press, 2022, 102: 181-231.
↑  Eng J, Kleinman W A, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas[J]. Journal of Biological Chemistry, 1992, 267(11): 7402-7405.